Tag Archives: Allergan

Unmet Need in the Migraine Space?

By Ben Comer | Published: February 3, 2012
Allergan CEO David Pyott is bullish on Botox’s potential as a salve for chronic migraine. He’s also betting on a next-gen dihydroergotamine (DHE) – Levadex – from MAP Pharmaceuticals.
Posted in FDA, Global, Marketing, Regulatory, Strategy, Technology | Also tagged , , , | 2 Comments

Allergan Offers to Pay Journos to Discuss Botox

By Ben Comer | Published: May 11, 2011
Physicians aren’t the only ones getting paid to attend industry-sponsored events heavy on product discussions. For $250, “select” journalists can discuss facial aesthetics at an event sponsored by Botox-maker Allergan, on June 9 in New York City. Journalistic ethics can be checked at the door. The emailed invitation to attend Allergan’s Facial Aesthetics Advisory Panel, which [...]
Posted in Events, Strategy, Uncategorized | Also tagged , , | 1 Comment

Feds Chase Down Faulty Skincare Promos

By George Koroneos | Published: August 26, 2009
FDA’s Division of Drug Marketing Communications, this week, posted a slew of warning and untitled letters to pharma firms for misleading skincare advertisements. Johnson & Johnson, Galderma, and Allergan each received a letter documenting complaints ranging from false advertising to unsubstantial efficacy claims. J&J received a violation letter in response to a journal ad for its [...]
Posted in FDA, Marketing | Also tagged , , , | 2 Comments